Pipeline

Translating vital scientific research into commercial applications

Imunon currently has two key products in the pipeline with an addressable market worth billions of dollars.

Highlights include:

  • IMNN-001 (formerly GEN-1), built on our TheraPlas® platform, has completed an Ovation Phase 1 Study, and recently read out results on the Ovation Phase 2 study establishing clinical POC for advanced ovarian cancer.
  • IMNN-101, built on the PlaCCine platform, is currently running a clinical POC for SARS-CoV-2.

Product Pipeline of DNA-based Transformative Medicines

3D model of a transparent cell

IMNN-001

IMNN-001 offers a novel way to harness the powerful immunological properties of IL-12: the “Master Switch” to the body’s immune system.

  • Six completed ovarian cancer trials demonstrate biologic and clinical activity
  • Safety and activity signals in Phase 1; Mechanism of action confirmed; Clinical proof of concept achieved in OVATION 2
  • OVATION 2 offers new hope for ovarian cancer patients. Topline data are promising, with data suggesting overall survival benefits of 11 months over standard of care
  • Now enrolling patients in Phase 3 trial studying 1st line indication for newly diagnosed ovarian cancer patients
View Program Information
View Phase 2 Publication
View Phase 1 Publication

IMNN-101

PlaCCine SARS-CoV-2 Proof Concept has demonstrated that our multicistronic formulated plasmid DNA platform can produce a robust immune response.

  • Preclinical evidence of IgG, neutralizing antibody and T-cell responses and protection against live virus challenge
  • Activity demonstrated with both single & bicistronic vectors
  • Evidence of greater than 12-month immunological durability</B.
  • Evidence of 12-month stability at 4ºC (ongoing study)
  • IMNN-101: Phase 1 POC clinical trial completed
View Product Information
3D model of coronavirus
close up of dna code

IMNN-201

We’ve initiated pre-clinical work for IMNN-201, based on our FixPlas platform, to develop a Trp2 tumor associated antigen cancer vaccine in melanoma. 

IP-Y

We’re preparing to initiate pre-clinical work for IP-Y, based on our IndiPlas platform, for the development of personalized (neoepitope) cancer vaccines.

virus and antibodies

Jeffrey W. Church

interim Chief Financial Officer

Jeffrey W. Church joined Imunon in July 2010 as Vice President and Chief Financial Officer. Mr. Church was appointed Senior Vice President and Chief Financial Officer of Imunon in July 2013. The appointment marked Mr. Church’s resumption of the role of Chief Financial Officer, a position he held prior to his promotion to Senior Vice President in July 2011, while also granting him responsibility for corporate investor relations. In 2018, Mr. Church was appointed Executive Vice President and Chief Financial Officer and Corporate Secretary and where he served in this capacity until his retirement in June 2024. In January 2026, Mr. Church was appointed interim Chief Financial Officer. He has over 30 years of experience in corporate finance, mergers and acquisitions, investor relations, and SEC reporting. Prior to joining Imunon, Mr. Church held senior financial executive positions with several private and public clinical-stage life science companies, including Alba Therapeutics Corporation, Novavax, Inc., GenVec, Inc., and Meridian Medical Technologies, Inc. Mr. Church started his career in 1979 with the public accounting firm Price Waterhouse. Mr. Church holds a BS degree from the University of Maryland and received his Maryland Certified Public Accountant accreditation in 1979.

Khursheed Anwer, PhD, MBA

Executive Vice President and Chief Science Officer

Khursheed Anwer, PhD, MBA, assumed the title of Executive Vice President and Chief Science Officer, upon Imunon’s June 2014 acquisition of EGEN, Inc., where he was President and Chief Science Officer, a position he held since 2009. He joined EGEN, Inc. in July, 2002, as Vice President of Research and Development, and directed the company’s clinical and research and development functions throughout his tenure at EGEN, Inc. Dr. Anwer has a PhD in Physiology/Pharmacology from Ohio University and received postdoctoral training from the University of Texas Health Science Center at Houston. Before joining EGEN, Inc., Dr. Anwer was Director of Pre-Clinical Development at Valentis, Inc. From 1993 to 1999, he served in several positions at GeneMedicine, Inc., where he led several research projects in the area of nonviral gene therapy. He has authored more than 40 publications in the area of nonviral gene therapy, resulting from his active career in research and development. Dr. Anwer has served as an adjunct faculty member in the Biology Department at the University of Alabama in Huntsville and a board member of the University of Alabama Business School, STEP.

Sebastien Hazard, M.D.

Executive vice president & chief Medical officer

Dr. Sebastien Hazard, M.D. was appointed Executive Vice President and Chief Medical Officer of Imunon in December 2023.  Prior to joining Imunon, Dr. Hazard served as Senior Vice President, Head of Clinical Development at Bicycle Therapeutics plc from April 2021 through September 2023.  Prior to joining Bicycle Therapeutics, Dr. Hazard served as Clinical Development Lead at GSK from June 2019 to April 2021.  He also served as Senior Medical Director of Clinical Development from July 2018 to May 2019, and Senior Medical Director of Global Medical Affairs from August 2016 to July 2018 at TESARO, Inc.  Dr. Hazard held various positions within Genentech including Medical Director in Lung Cancer of US Medical Affairs from November 2012 to July 2016.  Earlier in his career Dr. Hazard served as an advisor to the head of the French Drug Agency and to the French Health Minister’s cabinet.  Dr. Hazard holds a Doctorate in Medicine, Internal Medicine and Public Health from Paris VI Pitie Salpetriere an Executive MBA from INSEAD and Master’s degree in epidemiology and statistics applied to clinical research from Paris VI University.